Navin Fluorine International Limited has informed the Exchange about change in Management
NAVINFLUOR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Navin Fluorine International has announced a leadership change in its CDMO (Contract Development and Manufacturing Organisation) business. Mr. Rajendra Sahu, the current CEO of the CDMO Business, has resigned to pursue career prospects elsewhere and will be relieved effective September 20, 2025. In his place, Dr. Vijay Kaiwar has been appointed as CEO Designate of the CDMO Business effective August 25, 2025, and will formally take over as CEO from September 21, 2025. Dr. Kaiwar brings nearly 30 years of experience in CDMO and API businesses, having held senior roles at Anthem Biosciences, Sun Pharma, Aurobindo Pharma, and Jubilant Organosys. He holds a Ph.D. in Organic Chemistry from IICT Hyderabad and a Post-Doctoral Fellowship from King's College, London.
A smooth and planned CEO transition with an experienced external hire suggests continuity in the CDMO business, which is a key growth segment for the company. Investors may view the strong profile of Dr. Kaiwar positively, though the departure of the existing CEO could create short-term uncertainty about the CDMO business strategy.